register

News & Trends - MedTech & Diagnostics

Medtronic drug-coated balloon shows sustained and superior effectiveness

Health Industry Hub | April 26, 2021 |

MedTech News: Medtronic has reported that results from the study of its IN.PACT AV drug-coated balloon (DCB) showed sustained and superior effectiveness for two years in treating arteriovenous fistulae (AVF) lesions.

The data from the study showed that when compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native AVF in the upper extremity, the DCB exhibited longer and superior effectiveness.

Named IN.PACT AV Access Study, the prospective, global, single-blinded randomised controlled trial (RCT) enrolled a total of 330 participants at 29 sites in the US, Japan and New Zealand.

The 24-month data from 29 sites in the US, Japan and New Zealand showed that the IN.PACT AV DCB group had a continued clinical benefit versus the standard PTA control group.

Andrew Holden, Director of Interventional Radiology at Auckland Hospital and Associate Professor of Radiology at Auckland University said “A patient who receives haemodialysis will often need to have several reinterventions each year to maintain patency and keep critical access sites open and functioning properly.

“Being able to show these results at two years will ultimately impact standard of care for patients undergoing dialysis. For my patients, these durable results translate into fewer reinterventions and a better quality of life.”

Furthermore, 52.2% target lesion primary patency for two years was observed in the IN.PACT AV DCB group versus 36.2% in the PTA control group (p<0.001).

Dave Moeller, President of the Peripheral Vascular Health business, which is part of the Cardiovascular Portfolio at Medtronic said “These results are significant not only because IN.PACT AV is the only DCB to meet both safety and effectiveness endpoints through six months, but also because it demonstrates that at two years, IN.PACT AV does better than PTA in helping to keep critical lifelines open and reduce the number of times a patient needs to return to their physician for a reintervention.”


News & Trends - MedTech & Diagnostics

Policy paralysis: Private hospitals left to clean up the government’s mess on medical device reforms

Policy paralysis: Private hospitals left to clean up the government’s mess on medical device reforms

Health Industry Hub | April 17, 2025 |

Hospitals shouldn’t be forced to grovel to private health insurers to secure funding for essential, lifesaving medical devices. But thanks […]

More


News & Trends - Pharmaceuticals

Oncologists pioneer liquid biopsy-guided treatment in lung cancer

Oncologists pioneer liquid biopsy-guided treatment in lung cancer

Health Industry Hub | April 17, 2025 |

Lung cancer is Australia’s leading cause of cancer deaths. Local experts are set to lead a new frontier in personalised […]

More


Medical and Science

The high cost of record low research funding

The high cost of record low research funding

Health Industry Hub | April 17, 2025 |

Australia has delivered some of the world’s most transformative health and medical breakthroughs – the cochlear implant, the HPV vaccine, […]

More


News & Trends - Pharmaceuticals

UCB secures dermatology indication with first dual IL-17A/F inhibitor

UCB secures dermatology indication with first dual IL-17A/F inhibitor

Health Industry Hub | April 17, 2025 |

UCB’s IL-17A and IL-17F inhibitor has been added to the Australian Register of Therapeutic Goods (ARTG) for adults with moderate […]

More


This content is copyright protected. Please subscribe to gain access.